GSK Receives Breakthrough Therapy Designation for Blenrep

GSK plc has announced that China’s NMPA granted Breakthrough Therapy Designation for its drug Blenrep for treating relapsed multiple myeloma. This designation was awarded based on trial results indicating significant improvements in progression-free survival compared to existing treatments.

Date: 13-09-2024

AI Rating: 7

GSK plc (GSK) has achieved a milestone by receiving Breakthrough Therapy Designation from the NMPA in China for its drug Blenrep (belantamab mafodotin) when used in combination with bortezomib and dexamethasone. This designation is significant as it typically accelerates the development and review of drugs for serious or life-threatening conditions.

The designation was based on interim results from the phase III DREAMM-7 trial, which met its primary endpoint, showcasing statistically significant improvements in progression-free survival (PFS) for the combination therapy as compared to daratumumab with BorDex. This finding highlights the potential efficacy of Blenrep, which can positively influence investor sentiment as it suggests a competitive edge in the treatment of relapsed multiple myeloma.

While the report does not provide specific figures regarding earnings per share (EPS), revenue growth, net income, profit margins, free cash flow (FCF), or return on equity (ROE), the breakthrough designation can enable GSK to capture a more significant market share in the oncology sector, potentially leading to revenue growth. The global prevalence of over 180,000 new multiple myeloma cases each year adds urgency and market potential for therapies targeting this condition.

Stocks: GSK